Status:
COMPLETED
Etanercept SFP in RA Patients
Lead Sponsor:
Amgen
Collaborating Sponsors:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Purpose of this study is to evaluate the immunogenicity and overall safety of etanercept SFP therapy administered once weekly for 24 weeks to subjects with rheumatoid arthritis.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Men and women 18 years of age or older who have RA, as defined by the ACR criteria for classification of RA
- Naïve to etanercept therapy
- Able to self-inject investigational product or have a designee who can do so
- Ethical - Before any study-specific procedure, the appropriate written informed consent must be obtained Exclusion Criteria
- Receipt of Corticosteroids\> 10 mg/day of prednisone (or its equivalent) during 14 days befor 1st dose of investigational product
- Receipt of MTX witin 30 days of 1st dose of investigational product
- Receipt of an other investigational drug within 30 days of 1st dose
- Receipt of TNF inhibitor therapy within 90 days of 1st dose
- Receipt of cyclophosphamide within 6 mo of 1st dose
- Current use of nonsteroidal anti-inflammatory drugs (NSAIDs) greather than the maximum recommended dose in the product info sheet
- Current use of insulin
- gnificant concurrent medical condition
Exclusion
Key Trial Info
Start Date :
December 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2007
Estimated Enrollment :
224 Patients enrolled
Trial Details
Trial ID
NCT00413452
Start Date
December 1 2006
End Date
October 1 2007
Last Update
February 13 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.